InnoCare Pharma Ltd
HKEX:9969
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/S
Price to Sales (P/S) ratio shows how much investors pay for each dollar of a company`s sales. It`s calculated by dividing the company`s market value by its total revenue.
Price to Sales (P/S) ratio shows how much investors pay for each dollar of a company`s sales. It`s calculated by dividing the company`s market value by its total revenue.
Valuation Scenarios
If P/S returns to its 3-Year Average (15.5), the stock would be worth HK$24.03 (74% upside from current price).
| Scenario | P/S Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 8.9 | HK$13.83 |
0%
|
| 3-Year Average | 15.5 | HK$24.03 |
+74%
|
| 5-Year Average | 15.5 | HK$24.03 |
+74%
|
| Industry Average | 12.3 | HK$19.06 |
+38%
|
| Country Average | 2.8 | HK$4.28 |
-69%
|
Forward P/S
Today’s price vs future revenue
| Today's Market Cap | Revenue | Forward P/S | ||
|---|---|---|---|---|
|
HK$24B
|
/ |
Apr 2026
¥2.5B
|
= |
|
|
HK$24B
|
/ |
Dec 2026
¥2.5B
|
= |
|
|
HK$24B
|
/ |
Dec 2027
¥2.7B
|
= |
|
|
HK$24B
|
/ |
Dec 2028
¥3.9B
|
= |
|
|
HK$24B
|
/ |
Dec 2029
¥4.3B
|
= |
|
|
HK$24B
|
/ |
Dec 2030
¥5.6B
|
= |
|
|
HK$24B
|
/ |
Dec 2031
¥6.6B
|
= |
|
|
HK$24B
|
/ |
Dec 2032
¥7.8B
|
= |
|
Forward P/S shows whether today’s P/S still looks high or low once future revenue are taken into account.
Peer Comparison
| Market Cap | P/S | P/E | ||||
|---|---|---|---|---|---|---|
| CN |
|
InnoCare Pharma Ltd
HKEX:9969
|
22.5B HKD | 8.9 | 30.8 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
373.6B USD | 6 | 87.9 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
186.6B USD | 4.8 | 22.9 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
162.4B USD | 5.5 | 19.1 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
108.6B USD | 9 | 27.3 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
74.7B USD | 5.2 | 16.6 | |
| NL |
|
argenx SE
XBRU:ARGX
|
41.3B EUR | 11.6 | 37.4 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.1 | -61.8 | |
| AU |
|
CSL Ltd
ASX:CSL
|
60B AUD | 2.7 | 29.6 |
Market Distribution
| Min | 0 |
| 30th Percentile | 1.5 |
| Median | 2.8 |
| 70th Percentile | 5.4 |
| Max | 5 034 353.9 |
Other Multiples
InnoCare Pharma Ltd
Glance View
InnoCare Pharma Ltd., a beacon in the bustling world of biotech, epitomizes the fusion of scientific innovation and entrepreneurial vision. Born out of the relentless pursuit to tackle some of the world's most challenging diseases, the company is primarily focused on developing and commercializing novel therapies for cancer and autoimmune diseases. Founded in China, InnoCare leverages its robust research and development network to explore new frontiers in drug discovery, making targeted therapies that aim to meet significant unmet medical needs. The company thrives at the intersection of cutting-edge biotechnology and meticulous clinical trials, bridging the gap between complex scientific data and patient well-being. The business model of InnoCare Pharma revolves around the creation and commercialization of proprietary drug candidates. Revenue streams flow from strategic partnerships, licensing agreements, and ultimately, the sale of its innovative pharmaceutical products. By maintaining a synergistic blend of internal research efforts and external collaborations, InnoCare not only fortifies its pipeline of drug candidates but also expands its global footprint. Their flagship product, often leading the charge from theory to the shelves of hospitals, underscores the company’s commitment to transforming promising scientific research into tangible, life-saving treatments. Through successful navigation of regulatory processes and strategic market entry, InnoCare solidifies its position not just as a pharmaceutical creator, but as a catalyst for hope in combating severe health conditions.
